Mylan Pays $9M To Settle Paclitaxel Patent Suit

Law360, New York (July 6, 2004, 12:00 AM EDT) -- Mylan Laboratories has agreed to pay $9 million to Tapestry Pharmaceuticals Inc. and Australia-based Mayne Group Ltd's U.S. unit to settle a patent lawsuit over the cancer treatment paclitaxel.

Mylan, the largest maker of generic drugs in the U.S., said the payment will end a lawsuit pending in federal court in Pittsburgh. Under the settlement, Mylan will have a paid-up license to sell paclitaxel under Mayne's patents.

“The parties will promptly file stipulations of dismissal with prejudice with the U.S. District Court for the Western District...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.